ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Samsung BioLogics flouted accounting rules, says regulator

South Korean drugmaker disagrees and hints at lawsuit

The Samsung group counts Samsung BioLogics as a key member of the sprawling conglomerate.   © Reuters

SEOUL -- A South Korean financial watchdog said Thursday that contract drug manufacturer Samsung BioLogics violated accounting rules, recommending the dismissal of executives and a referral to prosecutors.

The Securities and Futures Commission has been investigating the Samsung group member's accounting practices concerning a joint venture with U.S. pharmaceutical company Biogen.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more